Key Takeaways:
GSK PLC (LSE:GSK, NYSE:GSK) reported first-quarter core earnings per share of 46.5 pence, beating analyst expectations by over 7 percent and reaffirming its full-year guidance for 2026.
The British pharmaceutical giant's performance was driven by strong sales in its respiratory and general medicines divisions, according to its Wednesday statement. The results come amid a strong reporting season for European drugmakers, with competitor AstraZeneca also beating its first-quarter profit expectations.
The company's first-quarter earnings of 46.5 pence per share comfortably exceeded the company-provided consensus forecast of 43.3 pence. While specific revenue figures were not detailed in the initial announcement, the performance provides a solid start to the year.
GSK reiterated its full-year 2026 forecast, projecting turnover growth between 3 percent and 5 percent. The company anticipates core operating profit and earnings per share to both increase by 7 percent to 9 percent, assuming constant exchange rates. This outlook is supported by expected low double-digit growth in its Specialty Medicines unit, which is projected to offset a low single-digit decline or stable performance in its Vaccines and General Medicines businesses.
The steady guidance from GSK contrasts with the more bullish updates from some financial firms this quarter, such as Barclays PLC, which also reported strong results.
The reaffirmed guidance signals management's confidence in its portfolio to navigate market pressures throughout 2026. Investors will look to the upcoming detailed earnings call for more color on segment performance and sales figures for key drugs.
This article is for informational purposes only and does not constitute investment advice.
